1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 32, 14/Aug/2025
  4. Article
Rapid communication Open Access
Like 0
Download

2025 theme: Vaccines

Abstract

A live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65 years. In early 2025, providers were alerted, a precaution for older persons was issued and vaccine guidance was updated. In May, following 11 additional SAEs reported outside the US, use in older persons was temporarily paused until 6 August 2025.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.32.2500543
2025-08-14
2025-08-15
/content/10.2807/1560-7917.ES.2025.30.32.2500543
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/32/eurosurv-30-32-2.html?itemId=/content/10.2807/1560-7917.ES.2025.30.32.2500543&mimeType=html&fmt=ahah

References

  1. Kaslow D. Accelerated BLA approval - IXCHIQ. Silver Spring: US Food and Drug Administration; 9 Nov 2023. Available from: https://www.fda.gov/media/173759/download?attachment
  2. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33(36):4398-405.  https://doi.org/10.1016/j.vaccine.2015.07.035  PMID: 26209838 
  3. US Government Code of Federal Regulations. Postmarketing reporting of adverse experiences (21 CFR 600.80). College Park: National Archives and Records Administration. [Accessed: 15 Jul 2025]. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600/subpart-D/section-600.80
  4. Centers for Disease Control and Prevention (CDC). About the Clinical Immunization Safety Assessment (CISA) Project. Atlanta: CDC; May 2025. Available from: https://www.cdc.gov/vaccine-safety-systems/hcp/cisa/index.html
  5. Office for Human Research Protections. Code of Federal Regulations. A point in time eCFR system. Washington DC: Department of Health and Human Services. [Accessed: 6 August 2025]. Available from: https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.102
  6. Hills S. Surveillance for adverse events following use of live attenuated chikungunya vaccine and its use among travelers. Atlanta: CDC; Apr 2025. Available from: https://www.cdc.gov/acip/downloads/slides-2025-04-15-16/04-Hills-chikungunya-508.pdf
  7. Schneider M, Narciso-Abraham M, Hadl S, McMahon R, Toepfer S, Fuchs U, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;401(10394):2138-47.  https://doi.org/10.1016/S0140-6736(23)00641-4  PMID: 37321235 
  8. Valneva Austria GmbH. Package insert – IXCHIQ. Vienna: Valneva Austria GmbH. [Accessed: 30 Jun 2025]. Available from: https://www.fda.gov/media/173758/download?attachment
  9. Walker WL, Hills SL, Miller ER, Fischer M, Rabe IB. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012-2016. Vaccine. 2018;36(29):4369-74.  https://doi.org/10.1016/j.vaccine.2018.04.038  PMID: 29891351 
  10. Begier EM, Burwen DR, Haber P, Ball R, Vaccine Adverse Event Reporting System Working Group. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. Clin Infect Dis. 2004;38(6):771-9.  https://doi.org/10.1086/381548  PMID: 14999618 
  11. Panning M, Grywna K, van Esbroeck M, Emmerich P, Drosten C. Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006. Emerg Infect Dis. 2008;14(3):416-22.  https://doi.org/10.3201/eid1403.070906  PMID: 18325256 
  12. Borgherini G, Poubeau P, Staikowsky F, Lory M, Le Moullec N, Becquart JP, et al. Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients. Clin Infect Dis. 2007;44(11):1401-7.  https://doi.org/10.1086/517537  PMID: 17479933 
  13. Lindsey NP, Rabe IB, Miller ER, Fischer M, Staples JE. Adverse event reports following yellow fever vaccination, 2007-13. J Travel Med. 2016;23(5):taw045.  https://doi.org/10.1093/jtm/taw045  PMID: 27378369 
  14. Ministère du Travail, de la Santé, des Solidarités et des Familles. Les autorités sanitaires retirent les personnes de 65 ans et plus des cibles de la campagne de vaccination contre le chikungunya avec le vaccin IXCHIQ à La Réunion et à Mayotte. [Health authorities are removing people aged 65 and over from the targets of the chikungunya vaccination campaign with the IXCHIQ vaccine in Réunion and Mayotte]. Paris: Ministère de la Santé; Apr 2025. French. Available from: https://sante.gouv.fr/actualites/presse/communiques-de-presse/article/les-autorites-sanitaires-retirent-les-personnes-de-65-ans-et-plus-des-cibles-de
  15. European Medicines Agency (EMA). EMA starts review of Ixchiq (live attenuated chikungunya vaccine). Amsterdam: EMA; 7 May 2025. Available from: https://www.ema.europa.eu/en/news/ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine
  16. US Food and Drug Administration (FDA). FDA and CDC recommend pause in use of Ixchiq (chikungunya vaccine, live) in individuals 60 years of age and older while postmarketing safety reports are investigated. Silver Spring: FDA; 9 May 2025. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-and-cdc-recommend-pause-use-ixchiq-chikungunya-vaccine-live-individuals-60-years-age-and-older
  17. European Medicines Agency. Ixchiq: temporary restriction on vaccinating people 65 years and older to be lifted. Amsterdam: EMA; 11 Jul 2025. Available from: https://www.ema.europa.eu/en/news/ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted
  18. Hills S. Evidence to Recommendations and proposed recommendations for use of virus-like particle chikungunya vaccine among adolescent and adult travelers. Atlanta: CDC; April 2025. Available from: https://www.cdc.gov/acip/downloads/slides-2025-04-15-16/02-Hills-chikungunya-508.pdf
Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Susan+L+Hills&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hills Susan L</a>, <a href="/search?value1=Rebekah+A+Sutter&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sutter Rebekah A</a>, <a href="/search?value1=Elaine+R+Miller&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Miller Elaine R</a>, <a href="/search?value1=Edwin+J+Asturias&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Asturias Edwin J</a>, <a href="/search?value1=Lin+H+Chen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Chen Lin H</a>, <a href="/search?value1=Beth+P+Bell&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bell Beth P</a>, <a href="/search?value1=Michael+M+McNeil&option1=author&noRedirect=true" class="nonDisambigAuthorLink">McNeil Michael M</a>, <a href="/search?value1=Jeffrey+Rakickas&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rakickas Jeffrey</a>, <a href="/search?value1=Melinda+Wharton&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wharton Melinda</a>, <a href="/search?value1=Sarah+Meyer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Meyer Sarah</a>, <a href="/search?value1=J+Erin+Staples&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Staples J Erin</a></span>. Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(32):pii=2500543. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.32.2500543" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.32.2500543</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 24 Jul 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 11 Aug 2025 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.32.2500543
/content/10.2807/1560-7917.ES.2025.30.32.2500543
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error